Aerosol Drug Therapy

Published on 01/06/2015 by admin

Filed under Pulmolory and Respiratory

Last modified 01/06/2015

Print this page

This article have been viewed 11051 times

Chapter 36

Aerosol Drug Therapy

Jim Fink

An aerosol is a suspension of solid or liquid particles in gas. Aerosols occur in nature as pollens, spores, dust, smoke, smog, fog, and mist.¹ A primary function of the upper airway and respiratory tract is to protect the lungs from invasion by these aerosols. In the clinical setting, medical aerosols are generated with atomizers, nebulizers, and inhalers—devices that physically disperse matter into small particles and suspend them into a gas. Aerosols can be used to deliver bland water solutions to the respiratory tract (see Chapter 35) or to administer drugs to the lungs, throat, or nose for local and systemic effect. This chapter focuses on the principles of aerosol drug therapy.

The aim of medical aerosol therapy is to deliver a therapeutic dose of the selected agent (drug) to the desired site of action. The indication for any specific aerosol is based on the need for the specific drug and the targeted site of delivery.¹ For patients with pulmonary disorders, administration of drugs by aerosol offers higher local drug concentrations in the lung with lower systemic levels compared with other forms of administration. Improved therapeutic action with fewer systemic side effects provides a higher therapeutic index.²

Characteristics of Therapeutic Aerosols

Effective use of medical aerosols requires an understanding of the characteristics of aerosols and their effect on drug delivery to the desired site of action. Key concepts include aerosol output, particle size, deposition, and a phenomenon known as aging.

Aerosol Output

The rate that aerosol is generated is a key parameter in aerosol administration. Aerosol output is defined as the mass of fluid or drug contained in aerosol produced by a nebulizer. Output is expressed as either a unit of mass leaving the nebulizer or as a proportion of the dose placed in the nebulizer. Output rate is the mass of aerosol generated per unit of time. Output varies greatly among different nebulizers and inhalers. For drug delivery systems, emitted dose describes the mass of drug leaving the mouthpiece of a nebulizer or inhaler as aerosol.

Aerosol output can be measured by collecting the aerosol that leaves the nebulizer on filters and measuring either their weight (gravimetric analysis) or quantity of drug (assay). Gravimetric measurements of aerosols are less reliable than drug assay techniques because weight changes resulting from water evaporation cannot be differentiated from changes in drug mass. A drug assay provides the most reliable measure of aerosol output.

A substantial proportion of particles that leave a nebulizer never reach the lungs. The ability of aerosols to travel through the air, enter the airways, and become deposited in the lungs is based on numerous variables ranging from particle size to breathing pattern. Understanding and skillful manipulation of these variables can greatly improve pulmonary delivery of aerosols.

Particle Size

Aerosol particle size depends on the substance for nebulization, the method used to generate the aerosol, and the environmental conditions surrounding the particle.³ It is impossible to determine visually whether a nebulizer is producing an optimal particle size. The unaided human eye cannot see particles less than 50 to 100 µm in diameter (equivalent to a small grain of sand). The only reliable way to determine the characteristics of an aerosol suspension is laboratory measurement. The two most common laboratory methods used to measure medical aerosol particle size distribution are cascade impaction and laser diffraction. Cascade impactors are designed to collect aerosols of different size ranges on a series of stages or plates. The mass of aerosol deposited on each plate is quantified by drug assay, and a distribution of drug mass across particle sizes is calculated. In laser diffraction, a computer is used to estimate the range and frequency of droplet volumes crossing the laser beam.

Because medical aerosols contain particles of many different sizes (heterodisperse), the average particle size is expressed with a measure of central tendency, such as mass median aerodynamic diameter (MMAD) for cascade impaction or volume median diameter (VMD) for laser diffraction. These measurement techniques of the same aerosol may report different sizes, so it is important to know which measurement is used. The MMAD and VMD both describe the particle diameter in micrometers (µm). In an aerosol distribution with a specific MMAD, 50% of the particles are smaller and have less mass, and 50% are larger and have greater mass.

The geometric standard deviation (GSD) describes the variability of particle sizes in an aerosol distribution set at 1 standard deviation above or below the median (15.8% and 84.13%). Most aerosols found in nature and used in respiratory care are composed of particles of different sizes, described as heterodisperse. The greater the GSD, the wider the range of particle sizes, and the more heterodisperse the aerosol. Aerosols consisting of particles of similar size (GSD ≤ 1.2) are referred to as monodisperse. Nebulizers that produce monodisperse aerosols are used mainly in laboratory research and in nonmedical industries.

Deposition

When aerosol particles leave suspension in gas, they deposit on (attach to) a surface. Only a portion of the aerosol generated and emitted from a nebulizer (emitted dose) may be inhaled (inhaled dose). A fraction of the inhaled dose is deposited in the lungs (respirable dose). Inhaled mass is the amount of drug inhaled. The proportion of the drug mass in particles that are small enough (fine-particle fraction) to reach the lower respiratory tract is the respirable mass. Not all aerosol delivered to the lung is retained, or deposited. A small percentage (1% to 5%) of inhaled drug may be exhaled. Whether aerosol particles that are inhaled into the lung are deposited in the respiratory tract depends on the size, shape, and motion of the particles and on the physical characteristics of the airways and breathing pattern. Key mechanisms of aerosol deposition include inertial impaction, gravimetric sedimentation, and brownian diffusion.1,3

Inertial Impaction

Inertial impaction occurs when suspended particles in motion collide with and are deposited on a surface; this is the primary deposition mechanism for particles larger than 5 µm. The greater the mass and velocity of a moving object, the greater its inertia, and the greater the tendency of that object to continue moving along its set path (Figure 36-1). When a particle of sufficient (large) mass is moving in a gas stream and that stream changes direction, the particle tends to remain on its initial path and collide with the airway surface.

Because inertia involves both mass and velocity, the higher the flow of a gas stream, the greater the tendency for particles to impact and be deposited in the airways. Turbulent flow patterns, obstructed or tortuous pathways, and inspiratory flow rates greater than 30 L/min are associated with increased inertial impaction. Turbulent flow and convoluted passageways in the nose cause most particles larger than 10 µm to impact and become deposited. This process produces an effective filter that protects the lower airway from particulates such as dust and pollen. However, particles 5 to 10 µm tend to become deposited in the oropharynx and hypopharynx, especially with the turbulence created by the transition of air as it passes around the tongue and into the larynx.

Sedimentation

Sedimentation occurs when aerosol particles settle out of suspension and are deposited owing to gravity. The greater the mass of the particle, the faster it settles (Figure 36-2). During normal breathing, sedimentation is the primary mechanism for deposition of particles 1 to 5 µm. Sedimentation occurs mostly in the central airways and increases with time, affecting particles 1 µm in diameter. Breath holding after inhalation of an aerosol increases the residence time for the particles in the lung and enhances distribution across the lungs and sedimentation. A 10-second breath hold can increase aerosol deposition 10% and increase the ratio of aerosol deposited in lung parenchyma to central airway by fourfold.⁴

FIGURE 36-2 Effect of mass on particle size. Large particles **(A)** are more susceptible to the force of gravity than smaller particles **(B),** which are more affected by the bombardment of molecules deposited by diffusion.

Diffusion

Brownian diffusion is the primary mechanism for deposition of small particles (<3 µm), mainly in the respiratory region where bulk gas flow ceases and most aerosol particles reach the alveoli by diffusion. These aerosol particles have very low mass and are easily bounced around by collisions with carrier gas molecules. These random molecular collisions cause some particles to contact and become deposited on surrounding surfaces. Particles 1 to 0.5 µm are so stable that most remain in suspension and are cleared with the exhaled gas, whereas particles smaller than 0.5 µm have a greater retention rate in the lungs.

Figure 36-3 summarizes the relationships between particle size and aerosol deposition in the respiratory tract. The depth of penetration and deposition of a particle in the respiratory tract tend to vary with size and tidal volume (V_T).⁵ With this knowledge, it may be possible to target aerosol deposition to specific areas of the lung by using the proper particle size and breathing pattern.

FIGURE 36-3 Range of particle size for common aerosols in the environment and the influence of inertial impactions, sedimentation, and diffusion. (Modified from Yu CP, Nicolaides P, Soong TT, et al: Effect of random airway sizes on aerosol deposition. Am Ind Hyg Assoc J 40:999, 1979.)

Rule of Thumb

The site of deposition in the respiratory tract varies with the size of the particle. Use of nebulizers that produce particles in a specific size range improves the targeting of aerosols for deposition to a desired site in the respiratory tract, as follows:

Desired Location	Recommended MMAD
Upper airway: nose, larynx, trachea	5 to >50 µm
Lower airways	2 to 5 µm
Parenchyma: alveolar region	1 to 3 µm
Parenchyma	<0.1 µm

Aging

Aerosols are dynamic suspensions. Individual particles constantly grow, shrink, coalesce, and fall out of suspension. The process by which an aerosol suspension changes over time is called aging. How an aerosol ages depends on the composition of the aerosol, the initial size of its particles, the time in suspension, and the ambient conditions to which it is exposed.

Aerosol particles can change size as a result of either evaporation or hygroscopic water absorption. The relative rate of particle size change is inversely proportional to the size of a particle, so small particles grow or shrink faster than large particles. Small water-based particles shrink when exposed to relatively dry gas. Aerosols of water-soluble materials, especially salts, tend to be hygroscopic, absorbing water and growing when introduced into a high-humidity environment.⁵

Particle size is not the only determinant of deposition. Inspiratory flow rate, flow pattern, respiratory rate, inhaled volume, ratio of inspiratory time to expiratory time (I : E ratio), and breath holding all influence where a particle of any specific size is deposited. The presence of airway obstruction is one of the greatest factors influencing aerosol deposition. It has been shown that total pulmonary deposition is greater in smokers and patients with obstructive airway disease than in healthy persons (Figure 36-4). Similarly, when inspiratory flow rates are constant, the deposition fraction of monodisperse aerosols increases with increased V_T, length of respiratory (inspiratory) period, and particle size (Figure 36-5).

FIGURE 36-4 Total lung deposition of a fine aerosol of particles 1 µm in diameter in healthy adults and in subjects with obstructive airway disease. Numbers over the bar indicate the percentage increase above normal value. *COPD,* Patients with chronic obstructive pulmonary disease; *Dp,* particle diameter; *SAD,* smoker with symptoms of small airways disease; f, respiratory rate; *V_T,* tidal volume. (Modified from Kim CS: Methods of calculating lung delivery and deposition of aerosol particles. Respir Care 45:695, 2000.)

FIGURE 36-5 Total lung deposition versus V_T and respiratory time at a fixed flow: respiratory flow (Q) = 250 ml/sec. *Dp,* Particle diameter. (Modified from Kim CS: Methods of calculating lung delivery and deposition of aerosol particles. Respir Care 45:695, 2000.)

These dynamic variables make it difficult to predict exactly what occurs to aerosol particles when they enter a gas stream and are inhaled. For this reason, prediction of actual aerosol deposition for an individual patient is difficult.

Quantifying Aerosol Delivery

As mentioned in the preceding sections, many characteristics of aerosols can account for the variances in quantity of aerosolized medication delivered to the patient. Although the precise amount of drug delivered to the patient’s airways can be difficult to determine, it can be measured in terms of the patient’s clinical response to aerosol drug therapy, including the desired therapeutic effects and any unwanted adverse effects. The amount of aerosol deposited to a patient’s airways can be quantified using specialized equipment and tests.

One approach used to quantify aerosol deposition to the human body (in vivo) involves scintigraphy, in which a drug is “tagged” with a radioactive substance (e.g., technetium), aerosolized, and inhaled. A scanner (similar to scanners used in nuclear medicine) measures the distribution and intensity of radiation across the device and the patient’s head and thorax. The result is a radiation map of aerosol deposition in the upper airway, the lungs (central and peripheral airways), and the stomach. This information is used to calculate the percentage of drug retained by the device and delivered to various areas in the patient.⁶

A less direct approach relates the systemic pharmacokinetic profile of a drug delivered by aerosol to an assay of the drug in a patient’s blood or urine over time. This method does not estimate actual lung delivery, but it provides insight into systemic drug levels achieved after aerosol administration. Care must be taken to differentiate drug absorbed through the lungs from drug absorbed through the gastrointestinal tract. Simple laboratory, or in vitro, models, which simulate a range of V_T values, inspiratory flow rates, I : E ratios, and respiratory rates, have been useful in predicting inhaled mass of drug and relative performance of nebulizers.⁷

Hazards of Aerosol Therapy

The primary hazard of aerosol drug therapy is an adverse reaction to the medication being administered (see Chapter 32). Other hazards to the patient include infection, airway reactivity, systemic effects of bland aerosols, drug concentration, and eye irritation. Care providers and bystanders risk these hazards as a result of exposure to secondhand aerosol drugs.

Infection

Aerosol generators can contribute to nosocomial infections by spreading bacteria by the airborne route.⁸ The most common sources of bacteria are patient secretions, contaminated solutions (i.e., multiple-dose drug vials), and caregivers’ hands. Offending organisms are primarily gram-negative bacilli, in particular, Pseudomonas aeruginosa and Legionella pneumophila (the cause of the highly virulent legionnaires’ disease).⁹

Various procedures can help reduce contamination and infection associated with respiratory care equipment. Guidelines from the U.S. Centers for Disease Control and Prevention (CDC) state that nebulizers should be sterilized between patients, frequently replaced with disinfected or sterile units, or rinsed with sterile water (not tap water) and air dried every 24 hours (see Chapter 4).

Airway Reactivity

Cold air and high-density aerosols can cause reactive bronchospasm and increased airway resistance, especially in patients with preexisting respiratory disease.¹⁰ Medications such as acetylcysteine, antibiotics, steroids, cromolyn sodium, ribavirin, and distilled water have been associated with increased airway resistance and wheezing during aerosol therapy. Administration of bronchodilators before or with administration of these agents may reduce the risk or duration of increased airway resistance.

The risk of inducing bronchospasm always should be considered when aerosols are administered. Monitoring for reactive bronchospasm should include peak flow measurements or percentage forced expiratory volume in 1 second (%FEV₁) before and after therapy; auscultation for adventitious breath sounds; observation of the patient’s breathing pattern and overall appearance; and, most essential, communicating with the patient during therapy to determine the perceived work of breathing.¹¹

Pulmonary and Systemic Effects

Pulmonary and systemic effects are associated with the site of delivery and the drug being administered. However, even bland aerosols present risk. Excess water can cause overhydration, and excess saline solution can cause hypernatremia. Animal data indicate that long-term, continuous administration of bland aerosols can cause localized inflammation and tissue damage, atelectasis, and pulmonary edema.

Preliminary assessment should balance the need versus the risk of aerosol therapy, especially among patients at high risk, such as infants, patients who are prone to fluid and electrolyte imbalances, and patients with atelectasis or pulmonary edema. For patients unable to clear their own secretions, suctioning or other airway clearance techniques may be indicated as an adjunct to aerosol therapy. Care must be taken to ensure that patients are capable of clearing secretions when the secretions are mobilized by aerosol therapy. Appropriate airway clearance techniques should accompany any aerosol therapy designed to help mobilize secretions (see Chapter 40).

Drug Concentration

During nebulization, the evaporation, heating, baffling, and recycling of drug solutions undergoing jet or ultrasonic nebulization increase solute concentrations.¹² This process can expose the patient to increasingly higher concentrations of the drug over the course of therapy and result in a larger concentration of drug remaining in the nebulizer at the end of therapy. This increase in concentration usually is time-dependent; the greatest effect occurs when nebulization of medications occurs over extended periods, as in continuous aerosol drug delivery.

Eye Irritation

Aerosol administration via a face mask may deposit drug in the eyes and cause eye irritation. In very rare cases, anticholinergic medications (see Chapter 32) have been suspected to worsen preexisting eye conditions, such as forms of glaucoma. Caution should be exercised when a face mask is used during aerosol drug therapy. In addition, special mask designs that have been shown to reduce drug deposition in the eyes or mouthpieces should be considered for at-risk patients.^13,14

Secondhand Exposure to Aerosol Drugs

Workplace exposure to aerosol may be detectable in the plasma of bystanders and health care providers. Repeated secondhand exposure to bronchodilators is associated with increased risk of occupational asthma. Institutions should develop and implement an occupational health and safety policy to minimize the risk of secondhand aerosol exposure for care providers and bystanders.15–17 Unless filters are placed in the expiratory limb, 40% of aerosol produced during mechanical ventilation is exhausted to the air of the intensive care unit.¹⁸ Implementation of an occupational health and safety policy could include using systems that introduce less aerosol to the atmosphere (pressurized metered dose inhalers [pMDIs], dry powder inhalers [DPIs], and breath-actuated nebulizers), filtering exhalation to contain aerosol, and using environmental controls.

Aerosol drug Delivery Systems

Effective aerosol therapy requires a device that quickly delivers sufficient drug to the desired site of action with minimal waste and at a low cost.¹⁹ Aerosol generators in use include pMDIs with or without spacers or holding chambers, DPIs, small and large volume (jet) nebulizers, hand-bulb atomizers (including nasal spray pumps), ultrasonic nebulizers (USNs), and vibrating mesh (VM) nebulizers as well as numerous emerging technologies.²

Clinicians are often exposed to competing and sometimes conflicting claims about the different delivery systems and may not be provided the information they need to select the correct system for a given situation. Because device selection can make the difference between successful and unsuccessful therapy, clinicians must have in-depth knowledge of the operating principles and performance characteristics of these various systems and how best to select and apply them.²⁰

Metered Dose Inhalers

The pMDI is the most commonly prescribed method of aerosol delivery in the United States. The pMDI is portable, compact, and easy to use and provides multidose convenience. A uniform dose of drug is dispensed within a fraction of a second after actuation and is reproducible throughout the canister life. The pMDI and actuator are designed for the specific drug formulation and dose volume to be delivered. Although the pMDI appears to be a simple device, it represents sophisticated technology and engineering. Although relatively easy to use, it is commonly misused by patients.

The pMDI is used to administer bronchodilators, anticholinergics, and steroids. More formulations of these drugs are available for use by pMDIs than for use with nebulizers. Properly used, pMDIs are at least as effective as other nebulizers for drug delivery. For this reason, pMDIs often are the preferred method for delivering bronchodilators to spontaneously breathing patients and patients who are intubated and undergoing mechanical ventilation.²¹

Most pMDIs are “press and breathe,” but there is increasing presence of a variation known as breath-actuated pMDIs. The basic components of pMDI are similar regardless of type, manufacturer, or active ingredient; commonly used pMDIs are shown in Figure 36-6.

FIGURE 36-6 Examples of commonly used pMDIs. A, Albuterol inhaler B, The ASMANEX TWISTHALER. (A, Courtesy Hemera, Thinkstock. B, Reproduced with permission of Schering Corporation, subsidiary of Merck & Co. All rights reserved. ASMANEX and TWISTHALER are registered trademarks of Schering Corporation.)

A pMDI is a pressurized canister that contains the prescribed drug (a micronized powder or aqueous solution) in a volatile propellant combined with a surfactant and dispersing agent (Figure 36-7). When the canister is inverted (nozzle down) and placed in its actuator, or “boot,” the volatile suspension fills a metering chamber that controls the amount of drug delivered. Pressing down on the canister aligns a hole in the metering valve with the metering chamber. The high propellant vapor pressure quickly forces the metered dose out through this hole and through the actuator nozzle.

FIGURE 36-7 Components of a pMDI, including function of the metering valve. (From Gardenhire DS: Rau’s respiratory care pharmacology, ed 8, St. Louis, 2012, Mosby.)

Aerosol production takes approximately 20 msec. As the liquid suspension is forced out of the pMDI, it forms a plume, within which the propellants vaporize, or “flash.” Initially, the velocity of this plume is high (approximately 15 m/sec). However, within 0.1 second, the plume velocity decreases to less than half its maximum as the plume moves away from the actuator nozzle. At the same time, propellant evaporation causes the initially large particles (35 µm) generated at the actuator orifice to decrease rapidly in size.

The output volume of pMDIs ranges from 30 to 100 mcl. Approximately 60% to 80% by weight of this spray consists of the propellant, with only approximately 1% being active drug (50 mcg to 5 mg, depending on the drug formulation). For a chlorofluorocarbon (CFC) pMDI used in a standard actuator, loss of drug in the valve stem housing and on the actuator mouthpiece amounts to 10% to 15% of the nominal dose from the metering valve.

From their inception in the mid-1950s to the beginning of the twenty-first century, chlorofluorocarbons (CFCs) such as Freon were the propellants used in pMDIs. Manufacture of CFCs for most applications was prohibited because of the effect of these compounds on global warming, with a period of transition provided for pMDIs. A consortium of eight pharmaceutical companies developed hydrofluoroalkane (HFA)-134a to be more environment-friendly and possibly clinically safer than CFCs.²² Redesign of key components of the pMDI has resulted in improved performance.²³

In addition to the propellant, pMDIs use dispersal agents to improve drug delivery by keeping the drug in suspension. The most common dispersal agents are surfactants, such as soy lecithin, sorbitan trioleate, and oleic acid. These agents help keep the drug suspended in the propellant and lubricate the valve mechanism but may also cause adverse responses (coughing or wheezing) in some patients.

Before initial use and after storage, every pMDI should be primed by shaking and actuating the device to atmosphere one to four times (see label for the specific device). Without priming, the initial dose actuated from a new pMDI canister contains less active substance than subsequent actuations.²⁰ This “loss of dose” from a pMDI occurs when drug particles rise to the top of the canister over time (“cream”). A reduction in emitted dose with the first actuation commonly occurs with a pMDI after storage, particularly with the valve pointed in the downward position. Loss of prime is related to valve design and occurs when propellant leaks out of the metering chamber during periods of nonuse (e.g., 4 hours). The result is reduced pressure and drug released with the next actuation.²⁰ Improved designs of metering valves developed for use with HFA propellants reduce these losses. It is recommended that a single dose be wasted before the next dose is inhaled when a CFC pMDI has not been used for 4 to 6 hours. An HFA pMDI requires no wasting of dose for periods exceeding 2 days.

Breath-Actuated Pressurized Metered Dose Inhaler

A variation of a pMDI is a breath-actuated model, which incorporates a trigger that is activated during inhalation. This trigger theoretically reduces the need for the patient or caregiver to coordinate MDI actuation with inhalation.²⁴ However, patients may stop breathing when the MDI is actuated (“cold Freon effect”) or have suboptimal inspiration. Evaluation of the efficacy of breath-actuated pMDIs in children younger than 6 years is limited, and their use should be restricted to older children and adults. Oropharyngeal deposition of steroids using these devices is still very high.

The Aerocount Autohaler is a flow-triggered pMDI developed and marketed by the 3M Corporation (St. Paul, MN) (Figure 36-8). The device is designed to eliminate the need for hand-breath coordination by automatically triggering in response to the patient’s inspiratory effort.²⁴ To use the Autohaler, the patient cocks a lever on the top of the unit, which sets in motion a downward spring force. Using the closed-mouth technique, the patient draws through the mouthpiece. When the patient’s flow rate exceeds 30 L/min, a vane releases the spring, which forces the canister down and triggers the pMDI. In the United States, the Autohaler is available only with pirbuterol, a bronchodilator similar to albuterol. Current data indicate that the device reduces pharyngeal impaction and enhances lung deposition. A possible limitation of the device is that it can be breath actuated only. Patients experiencing an acute exacerbation of bronchospasm may be unable to generate sufficient flows to trigger the Autohaler. This theoretical concern has not been widely observed in clinical studies of patients with severe exacerbation of asthma receiving treatment in emergency departments. Nevertheless, caution may be appropriate in ordering breath-triggered pMDIs for small children and patients prone to severe levels of airway obstruction.

FIGURE 36-8 Autohaler (3M, St Paul, MN) flow-triggered pMDI. (Modified from Gardenhire DS: Rau’s respiratory care pharmacology, ed 8, St. Louis, 2012, Mosby.)

The Easihaler (GlaxoSmithKline, Philadelphia) is a breath-actuated pMDI that has been developed with a range of medications and is currently available in Europe and Canada. Release in the United States is anticipated in the near future. A new generation of pMDIs such as the Tempo (MAP Pharmaceuticals, Mountain View, CA) have been designed to be breath actuated with lower force of the plume exiting the mouthpiece, reducing oropharyngeal deposition and increasing lung dose (Figure 36-9).

FIGURE 36-9 Tempo® Inhaler is a breath actuated pMDI with synchronous trigger for breath actuation and flow control chamber to reduce plume velocity. (Courtesy of MAP Pharmaceuticals. The TEMPO® inhaler is a registered trademark of MAP Pharmaceuticals, Inc. Mountain View, Calif.)

Dose Counters

A serious limitation of pMDIs is the lack of a “counter” to indicate the number of doses remaining in the canister. After the number of label doses have been administered, the pMDI may seem to give another 20 to 60 doses, which may deliver little or no medications as the doses “tail-off.” Tail-off effect refers to variability in the amount of drug dispensed toward the end of the life of the canister. The result of tail-off is swings from normal to almost no dose emitted from one breath to the next with no reliable indicator to the user. Without a dose counter, there is no viable method to determine remaining drug in a pMDI other than manually keeping a log of every dose taken. The U.S. Food and Drug Administration (FDA) is requiring all new pMDIs to have a counter technology to track pMDI actuations remaining. Third-party dose counters may be added to older pMDI models but may not have the accuracy of built-in technology (Figure 36-10).

Mini Clini

Using Universal Pressurized Metered Dose Inhaler Actuator or Boot

Problem

The association of CFCs with degradation of the earth’s atmosphere and the ozone layer has resulted in an international treaty banning use of these compounds. As HFAs become the propellants of choice, a problem arises. If the CFC and HFA drug formulations are bioequivalent, can these compounds be used with the same (universal) pMDI actuator, or boot?

Solution

In the case of HFA-based albuterol (e.g., Proventil HFA), the operating pressure and stem orifice differ from those used for the CFC formulation. The result is different plume geometries. When HFA albuterol is used in a universal adapter designed for CFC albuterol, the MMAD and GSD are greatly increased. The result is that significantly less drug is available to the patient. When possible, accessory devices that are used in the manufacturer’s boot with the pMDI should be selected. If these devices are unavailable, the universal adapter device that is available should be evaluated to determine how much additional dose may be required to provide an equivalent dose through a third-party adapter.

Factors Affecting Pressurized Metered Dose Inhaler Performance and Drug Delivery

Aerosol Delivery Characteristics

Although pMDIs can produce particles in the respirable range (MMAD 2 to 6 µm),²⁰ the initial velocity and dispersion of the aerosol plume generate larger particles that decrease in size as they leave the pMDI, resulting in approximately 80% of the dose leaving the actuator to impact and become deposited in the oropharynx. A significant proportion of this oropharyngeal deposition is swallowed and may be a factor in systemic absorption of some drugs. Pulmonary deposition ranges from 10% to 20% in adults and larger children (less in infants).²⁶ The exact amount of drug delivered to an individual patient is unpredictable because of high variability between patients and because pMDI drug administration is technique-dependent.

Technique

The successful administration of aerosol drugs by pMDI is highly technique-dependent. Two-thirds of patients and health care professionals who should teach pMDI use do not perform the procedure properly.²⁷ Box 36-1 outlines the recommended steps for self-administering a bronchodilator by simple pMDI. Thorough preliminary patient instruction can last 10 to 30 minutes and should include demonstration, practice, and confirmation of patient performance (demonstration pMDIs with placebo are available from manufacturers for this purpose). Repeated instruction improves performance; repeat instruction is done most appropriately with follow-up clinic or home visits. Demonstration and return demonstration must occur several times for best patient adherence to device use.

Box 36-1 Optimal Technique for Use of a Pressurized Metered Dose Inhaler

1. Warm the pMDI canister to hand or body temperature, and shake it vigorously.

2. Before first use of a new pMDI and when the pMDI has not been used for several days, prime the pMDI by pointing it into the air (away from people) and actuating.

3. Assemble the apparatus and uncap the mouthpiece, ensuring there are no loose objects in the device.

4. Open mouth technique *: Open your mouth wide, keeping tongue down. Hold the pMDI with the canister oriented downward and the outlet aimed at your mouth. Position the pMDI approximately 4 cm (two fingerbreadths) away from your mouth.

5. Closed mouth technique ^†: Place mouthpiece between lips, with tongue out of the path of the outlet.

6. Breathe out normally.

7. As you slowly begin to breathe in (<0.5 L/sec), actuate the pMDI.

8. Continue inspiration to total lung capacity.

9. Hold your breath for up to 10 seconds. Then relax and breathe normally.

10. Wait 1 minute between puffs.

11. Disassemble the apparatus, and recap the mouthpiece.

^*Technique is based on research with beta agonists and has been shown to reduce oropharyngeal deposition. It is not advised for use with anticholinergics because of possible eye exposure.

^†Label technique recommended by pMDI manufacturers.

For best effect, the pMDI should be actuated once at the beginning of inspiration. Common hand-breath coordination problems include actuating the pMDI before or after the breath. Some patients, especially infants, young children, elderly adults, and patients in acute distress, may be unable to coordinate actuation of the pMDI with inspiration. Some patients exhibit a “cold Freon effect,” which occurs when the cold aerosol plume reaches the back of the mouth and the patient stops inhaling. All of these problems reduce aerosol delivery to the lung to the point that the patient does not benefit from the medication, but they can be corrected entirely or in part by use of the proper pMDI accessory device.

Most pMDI labels call for placing the mouthpiece between the lips. However, research has shown that positioning the outlet of the pMDI approximately 4 cm (two fingerbreadths) in front of the mouth improves lung deposition by decreasing oropharyngeal impaction.²⁸ Holding the canister outside the open mouth (at two fingerbreadths) provides a space for the particles to decelerate while evaporating, allowing particle size to reduce to respirable size. Use of the open-mouth technique with a low inspiratory flow rate can result in a doubling of the dose delivered to the lower respiratory tract of an adult from approximately 7% to 10% to 14% to 20%. However, this technique is more difficult for patients to perform reliably than the closed-mouth technique. Although it may reduce oropharyngeal deposition, the technique has not been shown to improve the clinical response to pMDI bronchodilators.

Concerns have been raised about use of the open-mouth technique with ipratropium bromide because poor coordination can result in drug being sprayed into the eyes. Use of anticholinergic agents has been associated with increased ocular pressure, which could be dangerous for patients with glaucoma. For avoidance of ocular exposure, the drug manufacturer recommends patients use the closed-mouth technique with ipratropium.

The high percentage of oropharyngeal drug deposition with use of steroid pMDIs can increase the incidence of opportunistic oral yeast infection (thrush) and changes in the voice (dysphonia). Rinsing the mouth after steroid use can help avoid this problem, but most pMDI steroid aerosol impaction occurs deep in the hypopharynx, which cannot be easily rinsed with gargling. For this reason, steroid pMDIs should not be used alone but always in combination with a spacer or valved holding chamber. See Box 36-2 for instructions for determining dosage left in the pMDI.

Box 36-2 Determining Dose Left in Pressurized Metered Dose Inhaler

Tracking the number of actuations (puffs) remaining in a pMDI can be done with or without dose counters (see Figure 36-10).

With Dose Counters

The user should ²⁹:

1. Determine how many puffs of drug the pMDI has when full.

2. Learn to read the counter display because each dose counter has a different way of displaying doses left in the canister.

3. Check the counter display to track the pMDI actuations remaining in the canister.

4. Reorder the pMDI when there are a few days of drug remaining.

5. Dispose of the pMDI properly, after the last dose is dispensed.

Without Dose Counters